PRİMER DİSMENORE ŞİDDETİNE GÖRE VÜCUT İMAJININ, SANTRAL SENSİTİZASYONUN VE PSİKOSOSYAL PARAMETRELERİN KARŞILAŞTIRILMASI
Göster/ Aç
Tarih
2024Yazar
OFLAS KILIÇ, GÜLŞAH
Ambargo Süresi
Acik erisimÜst veri
Tüm öğe kaydını gösterÖzet
The aim of this study was to compare body image, central sensitization and psychosocial parameters according to the severity of primary dysmenorrhea (PD). The study included 100 patients. Moderate pain group and severe pain group (marking between 4-10 cm on the Visual Analog Scale (VAS)) were assigned to Group 1 (n:50, age: 20.05 ± 1.68, body mass index (BMI): 22.10 ± 3.49); the non-PD and mild pain group (marking between 0-4 cm on the (VAS) was assigned to Group 2 (n:50, age: 20.07 ± 1.49, body mass index (BMI): 21.82 ± 2.48) were included. Physical and demographic characteristics and menstrual information were recorded. GAS was used for pain assessment, Fremantle Low Back Awareness Questionnaire for body image, Central Sensitization Scale for central sensitization, Pain Catastrophizing Scale for pain catastrophizing, and Depression, Anxiety and Stress Scale-21 for depression, anxiety and stress levels. According to the study results, the physical and demographic characteristics of the groups were similar (p>0.05). Significant differences were found between the groups in terms of body image, central sensitization and psychosocial parameters (p<0.05). Compared to Group 2, Group 1 had lower body image perception, higher central sensitization, higher pain catastrophization, higher levels of depression, anxiety and stress. Our study results revealed findings that emphasize that pain catastrophization should be taken into account when approaching patients with PD, more attention should be paid to body image perception in the management and control of PD, and dysmenorrhea, which has negative effects on psychosocial status, should be addressed in all aspects. Determining whether PD patients show signs of central sensitization will shed light on the selection of appropriate treatment techniques, the development of new treatments, pain management and ideally the prevention of future chronic pain problems.